Previous studies have investigated the role of molecular markers in polyps for predicting the development of metachronous lesions, especially advanced adenomas, revealing an increased MACL risk in patients with KRAS-mutated polyps at baseline [5]. The gene discussed is KRAS; the disease is adenoma.